Blog
RSS FeedPosted by Michael Wonder on 19 Mar 2016
Addendum on regorafenib in metastatic colorectal cancer: added benefit no longer proven
17 March 2016 - The drug manufacturer presented further analyses; the additional disadvantages outweigh the survival advantage. ...
Posted by Michael Wonder on 19 Mar 2016
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
17 March 2016 - Study data subsequently submitted allow quantification / still major added benefit for women. ...
Posted by Michael Wonder on 17 Mar 2016
Decision to list galsulfase (Naglazyme) for mucopolysaccharidosis (MPS) VI
17 March 2016 - PHARMAC is pleased to announce the approval of an agreement with BioMarin Pharmaceutical Australia Pty Ltd to ...
Posted by Michael Wonder on 17 Mar 2016
Call for patient input on a submission from UCB for brivaracetam
17 March 2016 - CADTH has received notice of a pending submission from UCB for brivaracetam for the treatment of patients ...
Posted by Michael Wonder on 16 Mar 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: little additional value says Germany's IQWiG
15 March 2016 - TheIQWiG found more positive and negative patient-relevant outcomes, which tend to cancel each other. There ...
Posted by Michael Wonder on 16 Mar 2016
NICE consults on ‘no’ recommendation for skin cancer drug talimogene laherparepvec
16 March 2016 - NICE has today issued draft guidance not recommending talimogene laherparepvec (Imlygic, Amgen) as an option for people ...
Posted by Michael Wonder on 16 Mar 2016
Faster access to effective cancer treatments through new Cancer Drugs Fund
16 March 2016 - Proposals will see new clinically and cost effective cancer drugs approved for use on the NHS earlier ...
Posted by Michael Wonder on 16 Mar 2016
RFP - supply of bortezomib
16 March 2016 - PHARMAC invites proposals for the supply of bortezomib in New Zealand. ...
Posted by Michael Wonder on 15 Mar 2016
Secukinumab for active ankylosing spondylitis or psoriatic arthritis; no additional clinical benefit says Germany's IQWiG
15 March 2016 - Since Novartis cited no adequate studies, an additional benefit of secukinumab versus the appropriate comparator therapies has ...
Posted by Michael Wonder on 11 Mar 2016
Call for patient input on a submission from Hospira for a subsequent entry biologic
11 March 2016 - CADTH has received notice of a pending submission from Hospira for Inflectra (infliximab) for the treatment of ...
Posted by Michael Wonder on 11 Mar 2016
PBS statutory pricing changes
11 March 2016 - The presentation slides from the 4 March 2016 information session on recent PBS statutory pricing changes have ...
Posted by Michael Wonder on 11 Mar 2016
Proposal to list cinacalcet (Sensipar) on the Pharmaceutical Schedule for parathyroid carcinoma and calciphylaxis
11 March 2016 - PHARMAC is seeking feedback on a proposal to list cinacalcet (Sensipar) on the Pharmaceutical Schedule through a ...
Posted by Michael Wonder on 11 Mar 2016
PBAC Guidelines review
11 March 2016 - The assessment of co-dependent technology chapter of the draft revised PBAC Guidelines has now been published on ...
Posted by Michael Wonder on 09 Mar 2016
Agenda for the 16 March 2016 TC meeting
9 March 2016 - The Transparency Commission will consider the reimbursement of ceftolozane sulphate with tazobactam sodium (Zerbaxa), lumacaftor with ivacaftor ...
Posted by Michael Wonder on 09 Mar 2016
Call for patient input on a submission from Merck for a subsequent entry biologic
9 March 2016 - CADTH has received notice of a pending submission from Merck for etanercept for use by certain patients ...